This is a routine product collaboration announcement with no financial details. Monitor for future commercial adoption metrics or follow-on regulatory clearances for additional Imricor configurations in the U.S. to gauge potential revenue impact.
Price Chart
Executive Summary
Philips and Imricor announced the first commercially available Interventional MR (iMR) lab solution combining Philips' 1.5T MRI platform with Imricor's MR-compatible systems and consumables for cardiac interventions. This is a product collaboration announcement, not a financial event, and represents a strategic expansion of Philips' MRI capabilities into interventional procedures. No financial terms or revenue projections were disclosed, making this a routine product development milestone for a large-cap company like Philips.
Key Facts
- Philips and Imricor announced a new iMR lab solution combining Philips' 1.5T MRI platform with Imricor's portfolio of MR-compatible systems and consumables for cardiac interventions.
- The solution is commercially available immediately in CE-marked markets and, in some configurations, the U.S.
- The iMR lab solution is built on Philips' BlueSeal helium-free MRI technology.
- No financial terms, deal value, or revenue projections were disclosed in the press release.
Financial Impact
No financial terms disclosed; product collaboration with no stated revenue or deal value.
Risk Factors
- No financial terms disclosed, making it difficult to assess materiality.
- Regulatory clearances for additional configurations in the U.S. are pending and may face delays.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352083 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Press Release | $26.92 $24.55 | ▼ −8.80% | ▼ −8.30% | $23.92 (−11.14%) |
Aug 24, 2026 5w ago | Press Release | $27.43 $24.90 | ▼ −9.22% | ▼ −10.47% | $23.92 (−12.80%) |
Jul 27, 2026 9w ago | Press Release | $25.02 $27.52 | ▲ +9.99% | ▲ +6.69% | $23.92 (−4.40%) |
Jun 2, 2026 17w ago | Press Release | $25.43 $27.20 | ▲ +6.96% | ▲ +8.53% | $23.92 (−5.94%) |
May 15, 2026 20w ago | Court Ruling | $25.23 $26.69 | ▲ +5.79% | ▲ +3.67% | $23.92 (−5.19%) |
May 6, 2026 21w ago | Press Release | $27.23 $25.35 | ▼ −6.90% | ▼ −9.69% | $23.92 (−12.16%) |
Mar 23, 2026 27w ago | Press Release | $26.81 $28.48 | ▲ +6.23% | ▼ −1.19% | $23.92 (−10.78%) |
Feb 10, 2026 33w ago | Court Ruling | $32.91 $28.81 | ▼ −12.46% | ▼ −10.18% | $23.92 (−27.32%) |
Feb 10, 2026 33w ago | Court Ruling | $32.91 $28.81 | ▼ −12.46% | ▼ −10.18% | $23.92 (−27.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access